Cardiomyopathies: Current Treatment and Future Options: The Second Edition
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Cardiology".
Deadline for manuscript submissions: 15 March 2025 | Viewed by 29
Special Issue Editor
Interests: arrhythmogenic cardiomyopathy: current treatment and future options (Entresto, MR inhibitors); hypertrophic cardiomyopathy: current treatment (betablocker, verapamil, disopyramid) and future options (mavacamten, surgical options, gene therapy); dilated cardiomyopathy: the role of standard treatment and future options; amyloid cardiomyopathy; takotsubo cardiomyopathy; phospholamban cardiomyopathy; RBM20 cardiomyopathy; Lamin A/C cardiomyopathy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This is the second edition of “Cardiomyopathy: Current Treatment and Future Options” (https://www.mdpi.com/journal/jcm/special_issues/Cardiomyopathies_Treatment_Future_Options).
According to the newest ESC guidelines (from 2023), recognized cardiomyopathies include hypertrophic cardiomyopathy, dilated cardiomyopathy, restrictive cardiomyopathy, arrhythmogenic right-ventricular cardiomyopathy, and non-dilated left-ventricular cardiomyopathy. Takotsubo cardiomyopathy and non-compaction cardiomyopathy should not be counted as cardiomyopathies.
We will discuss current key topics in hypertrophic, dilated, and restrictive cardiomyopathy.
The term “arrhythmogenic cardiomyopathy” has been withdrawn from use. It is no longer appropriate to use the terms “right-dominant arrhythmogenic cardiomyopathy”, “biventricular arrhythmogenic cardiomyopathy”, or “left-dominant arrhythmogenic cardiomyopathy”. These conditions should be discussed in broader terms.
Genetic counseling will be carried out in all patients, with different cardiomyopathies, and we will discuss the use of the names “desmoplakin cardiomyopathy”, “phospholamban cardiomyopathy”, “TMEM43 cardiomyopathy”, and so on to describe different features of a known genetic disease.
Prof. Dr. Stefan Peters
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hypertrophic cardiomyopathy
- dilated cardiomyopathy
- restrictive cardiomyopathy
- amyloid cardiomyopathy
- arrhythmogenic right ventricular cardiomyopathy
- non-dilated left ventricular cardiomyopathy
